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ABSTRACT In 2025, approximately one out of ﬁve adults will be obese. Physiologi-
cal changes associated with obesity have been shown to inﬂuence the pharmacoki-
netics of drugs. Anidulafungin is frequently used in critically ill patients, and to
achieve optimal efﬁcacy, it is essential that its dose is appropriate for each patient’s
characteristics. We combined data from obese subjects with data from normal-
weight subjects and determined an optimal dosing regimen for obese patients by
population pharmacokinetic modeling. Twenty adults, 12 of which were normal-
weight healthy subjects (median weight, 67.7 kg; range, 61.5 to 93.6 kg) and 8 of
which were morbidly obese subjects (median weight, 149.7 kg; range, 124.1 to 166.5
kg) were included in the analysis. Subjects received a single dose of 100 mg anidulafun-
gin intravenously over 90 min, upon which blood samples were obtained. Monte Carlo
simulations were performed to optimize dosing in obesity. A three-compartment model
and equal volumes of distribution described the data best. Total body weight was iden-
tiﬁed as a descriptor for both clearance and the volume of distribution, but the effect of
weight on these parameters was limited. Simulations showed that with the licensed
100-mg dose, more than 97% of subjects with a weight above 140 kg will have an area
under the concentration-time curve from 0 to 24 h of less than 99 mg · h/liter (the refer-
ence value for normal-weight individuals). We found that in obese and normal-weight
subjects, weight inﬂuenced both of the anidulafungin pharmacokinetic parameters clear-
ance and volume of distribution, implying a lower exposure to anidulafungin in (mor-
bidly) obese individuals. Consequently, a 25% increase in the loading and maintenance
doses could be considered in patients weighing more than 140 kg.
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The worldwide prevalence of obesity, which is a body mass index (BMI) above 30kg/m2, has tripled over the past 40 years, and morbid obesity is starting to appear
worldwide. The prevalence of obesity increased from 3.2% in 1975 to 10.8% in 2014 for
men and from 6.4% to 14.9% for women. Morbid obesity was virtually nonexistent in
1975, with an estimated prevalence of 0.0 to 0.5%, which increased to 0.8% for men and
1.8% for women in 2014. If this rate of increase persists, by 2025, approximately one in
every ﬁve individuals will be obese (1). Because obese patients are more susceptible to
nosocomial infections and are more prone to develop complications due to common
infections, an increase in the number of hospitalized obese patients with serious
infections can be expected (2). It is well established that obesity results in physiological
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changes that have a clinically relevant impact on the pharmacokinetics (PK) of many
drugs, including antimicrobial agents, such as micafungin and cefazolin (3–5). It is
therefore important to understand the impact of obesity on the PK of antimicrobial
agents.
Anidulafungin is one of the three available echinocandin antifungal agents and is
licensed for use as an intravenous (i.v.) treatment for invasive candidiasis in adult
patients at an initial 200-mg loading dose followed by 100 mg daily. Its efﬁcacy is
putatively driven by the ratio of the area under the concentration-time curve (AUC)
over the MIC (6). With the emergence of echinocandin resistance, it is essential to
adequately dose patients (with any given weight) for optimal efﬁcacy (7).
Contrary to the recommendations for caspofungin, no dose increase based on a
higher total body weight (TBW) is recommended by the manufacturer (8). Recently, we
described the anidulafungin PK in eight morbidly obese subjects with weights ranging
from 124 to 167 kg, determined using a noncompartmental approach, and we found
that exposure was, on average, 32.5% lower in those subjects than the reported
exposures in the general population (9). In the current study, we combined data from
this study in obese subjects (9) with data from two phase I PK studies in normal-weight
subjects and analyzed the data using nonlinear mixed-effects modeling. The aim of this
study was to determine whether and to what extent the pharmacokinetics of anidu-
lafungin are inﬂuenced by obesity (10) and to propose an optimal dosing regimen for
overweight, obese, and morbidly obese individuals.
RESULTS
Data for analysis. A total of 283 anidulafungin plasma concentrations were ob-
tained from 20 study participants (195 observations in 12 normal-weight subjects and
88 observations in 8 obese subjects). Patient characteristics are summarized in Table 1.
The mean TBW was 67.7 kg (range, 60.5 to 93.6 kg) and 149.7 kg (range, 124.1 to 166.5
kg) for the normal-weight and obese subjects, respectively. None of the plasma
samples had values below the limit of quantiﬁcation, and two samples were removed
from the data before model building because of a possible sampling error.
Population pharmacokinetic model. A three-compartment model with ﬁrst-order
elimination from the central compartment and an additive error model on the log scale
ﬁtted the data best. As the volumes of distribution (V) of the three compartments were
similar (i.e., volume of distribution of the central compartment [V1], 19.5 liters; volumes
of distribution of peripheral compartments [V2 and V3], 25.8 liters for V2 and 17.2 liters
for V3) but were estimated with a relative high imprecision (relative standard error of
the estimate, 50%). We therefore simpliﬁed the model by equalizing V1, V2, and V3.
This model resulted in a similar model ﬁt and goodness-of-ﬁt (GOF) plots. Interindi-
vidual variability (IIV) was estimated for clearance and all three volumes of distribution.
The use of a residual error for each separate study rather than one residual error
resulted in a 46-point decrease in the objective function value (OFV) (P  0.0001).
Parameter estimates of the structural model are provided in Table 2.
TABLE 1 Summary of subject demographics
Baseline characteristic
Values for:
Normal-wt subjects (n  12) Obese subjects (n  8)
No. (%) of subjects by sex
Male 10 (83.3) 3 (37.5)
Female 2 (16.7) 5 (62.5)
Median (range) values for:
Age (yr) 24.5 (21–30) 43 (29–66)
Total body wt (kg) 67.7 (60.5–93.6) 149.7 (124.1–166.5)
Ht (cm) 177 (164–188) 170.5 (159–190)
Body mass index (kg/m2) 22.4 (20.3–27.3) 49.1 (40.0–57.6)
Lean body wt (kg)a 55.7 (39.3–70.0) 66.4 (55.4–91.0)
aAccording to the formula of Janmahasatian et al. (10).
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Covariate model. Exploration using scatter plots of empirical Bayesian estimates for
clearance and volume of distribution versus TBW indicated a relation for both clearance
and the volume of distribution of the central compartment (Fig. 1). Inclusion of TBW as
a covariate on clearance lowered the IIV by 20%, from 15.4% (95% conﬁdence interval
[CI,], 8.4 to 20.2%) to 12.5% (95% CI, 4.5 to 17.7%), and lowered the IIV on the volume
of distribution by almost 50%, from 21.1% (95% CI, 14.2 to 26.4%) to 10.0% (95% CI, 5.5
to 14.2%). Both clearance and V1 were found to change with TBW using a power
function with an estimated exponent of 0.322 (95% CI, 0.17 to 0.50) and 0.631 (95% CI,
TABLE 2 Pharmacokinetic parameter estimates of the structural and ﬁnal modelsb
Parameter
Structural model Final model
Value
(% RSE) 95% CI Value (% RSE) 95% CI
Typical value
CL (liters/h) 1.08 (3.9) 0.99–1.16
CL70 kg  (TBW/70)1 (liters/h)
CL70 kg 0.996 (4.2) 0.91–1.09
1 0.322 (22.6) 0.169–0.496
V1 (liters) 18.9 (4.7) 17.2–20.6
V1, 70 kg  (TBW/70)2 (liters)
V1, 70 kg 16.6 (2.8) 15.6–17.6
2 0.631 (15.6) 0.386–0.834
V2  V3 (liters) Equal to V1 Equal to V1, 70 kg
Q1 (liters/h) 0.153 (6.2) 0.133–0.173 0.153 (6.4) 0.13–0.18
Q2 (liters/h) 15.7 (6.1) 13.7–17.7 14.1 (7.0) 12.2–16.0
Interindividual variabilitya (%)
CL 15.4 (34.7) 8.4–20.2 12.5 (50.3) 4.5–17.7
V 21.1 (28.6) 14.2–26.4 10.0 (39) 5.5–14.2
Residual error (%)
add study 1 12.6 (20.8) 9.4–15.1 11.0 (16.5) 9.0–13.1
add study 2 4.4 (18.4) 3.3–5.3 4.4 (19.3) 3.2–5.5
add study 3 8.4 (10.3) 7.4–9.3 8.7 (14) 7.1–10.0
OFV 931 975
a Calculated by e21, where 2 represents the variance.
bThe eta and epsilon shrinkages of the interindividual variability for CL and V, and all three residual errors
were all below 10%. Abbreviations: CL, clearance; CL70 kg, CL standardized to that for a typical 70-kg
individual; V1, volume of distribution of the central compartment; V2 and V3, volumes of distribution of
peripheral compartments; V1, 70 kg, volume of distribution of the central compartment standardized to that
for a typical 70-kg individual; Q1, intercompartmental clearance between V1 and V2; Q2, intercompartmental
clearance between V1 and V3; add, additive error on log scale; RSE, relative standard error based on the
covariance step in NONMEM; 95% CI, 95% conﬁdence interval obtained from nonparametric bootstrap
analysis (n  1,000); OFV, objective function value.
FIG 1 Individual empirical Bayes estimates for clearance (A) and volume of distribution (B) versus total body weight from the
structural model (dots) and ﬁnal model-predicted relationship (line).
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0.39 to 0.83), respectively. The GOF plots of the ﬁnal model can be found in Fig. 2 and
show no major deviations.
The results from nonparametric bootstrap analysis, listed in Table 2, show the
precision of the parameters in our population. The prediction-corrected visual predic-
tive check (pcVPC), shown in Fig. 3, demonstrates the validity of the ﬁnal model. The
95% CIs of the simulations are consistent with the median and 5th and 95th percentiles
of the observed concentrations. The width of the 95% CI seems to describe the
variation in observed concentrations adequately.
Monte Carlo simulation. Figure 4 shows the distribution of the median (interquar-
tile range [IQR]) AUC from 0 to 24 h (AUC0–24) on day 14 after administration of the
licensed 200-mg loading dose and daily 100-mg maintenance dose with increasing
weight from a 60-kg to a 170-kg TBW. The median AUC0–24 for typical normal-weight
subjects with weights between 60 and 80 kg was 99 mg · h/liter (IQR, 91 to 108 mg ·
h/liter) (Fig. 4). Figure 4 illustrates that virtually all subjects with a weight above 160 kg
had an AUC0–24 below the median for normal-weight subjects. Furthermore, the
median AUC0–24 for the subject group with weights between 140 and 150 kg fell below
the 80% AUC0–24 for the normal-weight reference group. In addition, more than 97%
of these subjects had an AUC0–24 below the 99-mg · h/liter median. Figure 5 shows the
change in AUC0–24 when subjects with a total body weight above 140 kg received a
25% dose increase. This augmented dose gave a level of exposure to anidulafungin in
subjects weighing up to 170 kg similar to the exposure typically observed in subjects
weighing 60 to 80 kg.
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FIG 2 Goodness-of-ﬁt diagnostics of the ﬁnal population pharmacokinetic model of anidulafungin in normal-weight (ﬁlled squares) and morbidly obese (open
squares) adult subjects. (A) Individual predicted concentration versus observed concentration; (B) population predicted concentration versus observed
concentration; (C) conditional weighted residuals (CWRES) versus population predicted concentration; (D) conditional weighted residuals versus time after dose.
Broken lines, a locally weighted least-squares regression; solid lines, the line of identity.
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DISCUSSION
We report here the ﬁrst population pharmacokinetic model to describe the behavior
of anidulafungin in subjects with a wide weight range (60.5 to 166.5 kg). Previous
investigations in obese subjects lacked data for normal-weight subjects and were able
to make a direct comparison only of average PK parameters. In doing so we improved
the analysis of the effects of weight on, especially, clearance and, as a consequence,
were able to provide a better suggestion for optimal dosing in (morbidly) obese
patients.
The relationship between clearance and body size was best described using a power
function on TBW with an exponent of 0.322. The relatively small exponent on TBW
indicates only a minor effect of weight on clearance, as visualized in Fig. 1A. In addition,
TBW explained approximately 20% of the interindividual variability in our population.
These results may be explained by the fact that anidulafungin is mainly cleared from
the plasma by slow spontaneous chemical degradation and that only a minor fraction
(10%) is cleared by excretion of unchanged drug in the feces (11). As a consequence,
it can be anticipated that changes in body composition are only of minor inﬂuence in
the degradation process. The impact of body weight on the unchanged fraction of
anidulafungin excreted in the feces could offer an explanation, but the effect size is
unknown and has not been reported.
Previous studies also found a signiﬁcant increase in clearance and, consequently, a
lower AUC at increasing weight (12, 13). Although these studies had sample sizes much
larger than the sample size in the present study, we are of the opinion that these
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FIG 3 Prediction-corrected visual predictive check for the ﬁnal pharmacokinetic model of anidulafungin, based on 1,000 simulations.
Prediction-corrected simulated (shaded areas) and observed (squares and dashed lines) anidulafungin concentrations versus time after
dosing in normal-weight (ﬁlled squares) and morbidly obese (open squares) adult subjects. The middle dashed line connects the median
values per bin. The outer dashed lines connect the 5th and 95th percentiles of the observations. The shaded areas are the 95% conﬁdence
intervals for the 5th and 95th percentiles and the median. (Inset) Expanded view of data from 0 to 24 h.
Pharmacokinetics of Anidulafungin in Obese Adults Antimicrobial Agents and Chemotherapy
July 2018 Volume 62 Issue 7 e00063-18 aac.asm.org 5
 o
n
 January 24, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
studies are inconclusive with regard to the impact of body weight, as both median
body weight and the body weight range were low (median weights in the studies
described in references 12 and 13, 60 and 68 kg, respectively). In addition, the results
might be obscured, as an increased clearance can also be attributed to an underlying
illness, as reported previously in critically ill patients (14–16).
An increased clearance and a larger volume of distribution were also reported in
critically ill patients with suspected or proven fungal infection in three studies, with the
AUC0–24 values being 69.8 mg · h/liter (14), 82.7 mg · h/liter (15), and 92.7 mg · h/liter
(16). The combination of critical illness and obesity further predisposes an individual to
suboptimal exposure. This was exempliﬁed by an investigation by Liu et al., who
reported a single case of a 240-kg patient receiving 150 mg anidulafungin daily with an
AUC of 55.3 mg · h/liter (16). A dose increase of 50% was suggested for patients
weighing more than 200 kg or patients with a BMI of 80 kg/m2 (16). However, this
begs the question whether this minor increase in dose is enough when treating
critically ill obese patients, given that it is known that anidulafungin has relatively few
side effects (8). This becomes more relevant in fungal infections with less susceptible
perpetrators (7, 14–16).
While no threshold value for exposure has been determined for anidulafungin, in a
population pharmacokinetic-pharmacodynamic analysis by Liu, a trend of a positive
association between exposure and efﬁcacy was found for anidulafungin (17). Due to the
relatively small sample size, a target AUC could not be estimated (17). In the absence
of well-deﬁned targets, we chose another approach to safeguard identical exposure.
This is a pragmatic bioequivalence-like approach and aimed for a dosing regimen that
ensures an appropriate AUC of approximately 99 mg · h/liter, comparable to that in
normal-weight subjects. Using this approach, our investigation showed that a 25% dose
increase in patients with weights above 140 kg and up to 170 kg both at the start and
during maintenance should lead to an exposure comparable to that in the general
normal-weight patient population. This dose adjustment could be implemented by
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increasing the daily dose. However, the costs of anidulafungin are not to be ignored. To
reduce the costs associated with the discarding of half-empty vials, alternate strategies
of repetitive cycles of 200 mg followed by three doses of 100 mg might provide a
suitable alternative (18), thereby achieving an equivalent cumulative exposure over 4
days.
This study has a few limitations. We investigated a relatively small group of 8 obese
subjects and 12 normal-weight subjects, with the latter mainly consisting of males
(83%) between 21 and 30 years old. The observed increase in both clearance and
volume of distribution was estimated using a power function with an estimated
exponent instead of the frequently used ﬁxed allometric exponent of 0.75 on clearance
and 1 on volume of distribution. Although our study lacks external validation to conﬁrm
these exponents, we did ﬁnd values for clearance that corresponded to those pre-
sented in previous reports of studies in both 60- and 150-kg adults (17). Because of a
lack of external validation, we report values for exposure only up to a weight of 170 kg,
the maximum weight in our population. For individuals with weights above 170 kg, the
relationship will hold but the uncertainty will increase. Furthermore, the allometric
exponent of 1 on the volume of distribution for (morbidly) obese individuals can be
debated, as these individuals are not simply bigger but have a different body compo-
sition with a different ratio of muscle, water content, and adipose tissue (19).
In summary, in our internally validated PK model for obese and normal-weight
subjects, weight was found to inﬂuence both clearance and volume of distribution. This
leads to lower exposure to anidulafungin in (morbidly) obese individuals. As a conse-
quence, a 25% increase in both the loading and maintenance doses could be consid-
ered in patients weighing more than 140 kg.
MATERIALS AND METHODS
Subjects and patients. Data from three studies, one study in obese patients (the ADOPT study) and
two studies in healthy controls (the VER002-1 and XBAE studies) (Pﬁzer, Inc., data on ﬁle), were combined
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FIG 5 Area under the concentration-time curve (AUC) of anidulafungin at steady state on day 14 based on simulations in 55,000 subjects.
Subjects weighing up to 140 kg received the standard 200-mg loading dose on day 1 followed by 100 mg daily. Subjects weighing more
than 140 kg received a 25% dose increase to a 250-mg loading dose on day 1 followed by 125 mg daily. The horizontal dashed lines
represents the exposure of 99 mg · h/liter, typically found in subjects weighing between 60 and 80 kg, and the 80% to 125% range of
this median value. The vertical dashed line shows the cutoff for the 25% dose increase. The boxes represent the 25th, 50th (median), and
75th percentiles, and whiskers represent the highest and lowest values within 1.5 times the interquartile range.
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for our current analysis. In the ADOPT study, obese Caucasian subjects (BMI  40 kg/m2) were given 100
mg anidulafungin i.v. over 90 min several hours prior to bariatric surgery and were sampled until 48 h
postinfusion (9). The two healthy volunteer studies in normal-weight Caucasian subjects also involved a
100-mg i.v. dose administered over 90 min (20). The VER002-1 study was a multiple-dose study, from
which we used the 24-h sampling PK data measured after administration of the initial 100-mg dose. The
XBAE study was a single-ascending-dose study. We used the data measured after administration of the
100-mg dose with sampling up to 168 h. The data that were used for modeling are summarized in Table
3. All studies were conducted in accordance with the Declaration of Helsinki. All study participants
provided written informed consent before inclusion, ethical approval was provided for each of the
original studies, and all data were analyzed anonymously.
Analytical assay. Anidulafungin plasma concentrations were quantiﬁed using validated assays. In
the ADOPT study, samples were analyzed by ultraperformance liquid chromatography with ﬂuorescence
detection as described before (9). The samples in the VER002-1 study were measured by high-
performance liquid chromatography (HPLC) with UV detection at 300 nm. The assay was validated over
a concentration range of 0.02 to 51.20 mg/liter and had an interday accuracy of between 95.5 and 101%,
precision of between 1.33 and 11.6%, and recovery of between 80.3 and 82.3%. The samples in the XBAE
study were analyzed by a validated HPLC with ﬂuorescence detection (excitation wavelength, 310 nm;
emission wavelength, 450 nm) assay with a concentration range of 0.005 to 10.00 mg/liter. Interday
accuracy, obtained during a 3-day validation, was 98.5 to 109.8%, while precision was 3.3 to 12.2% with
a 59 to 64% recovery.
Structural pharmacokinetic model. All data were analyzed using the nonlinear mixed-effects
software package NONMEM (version 7.3.0; Icon Development Solutions, Ellicott City, MD) and PsN
software (version 4.4.8) with PiranaJS (version 1.01) as an interface (21). R (version 3.2.4) was used for
graphical processing of the data and the NONMEM output. In NONMEM, the ADVAN 5 option and the
ﬁrst-order conditional estimation method were used for all model runs. Models with one, two, and three
compartments were explored and evaluated by visual inspection of the data. All random effects were
assumed to be lognormally distributed. Concentration data were log transformed, and we used an
additive error model in the log domain to describe the residual variability. Model selection was based on
the following goodness-of-ﬁt (GOF) criteria: (i) successful minimization and a successful covariance step,
(ii) visual inspection of diagnostic plots (observed versus individual and population predicted concen-
trations and conditional weighted residuals versus time and population predicted concentrations), (iii)
the precision of the parameter estimates, and (iv) a decrease of the objective function value (OFV) of at
least 3.84 (chi-squared, 1 degree of freedom, P  0.05). Candidate models were further evaluated by use
of a prediction-corrected visual predictive check (pcVPC) based on 1,000 Monte Carlo simulations.
Pharmacokinetic model with covariates. After developing the structural and statistical model, a
covariate analysis was performed using weight-derived parameters. The relationship between individual
empirical Bayes estimates for clearance and volume of distribution versus TBW and other commonly
investigated weight-derived parameters, such as BMI, lean body weight (LBW) (10), and body surface area
(BSA) (22), was examined in scatter plots. Linear and power functions with ﬁxed (allometric) or estimated
exponents were investigated and standardized to a typical 70-kg male with a height of 1.8 m. Stepwise
covariate modeling was performed by the use of forward inclusion and backward elimination steps. For
inclusion of the covariate in the model, covariates were included one at a time, using a P value cutoff of
0.005 (OFV decrease, at least 7.9), together with GOF scatter plots and evaluation of plots of post hoc
estimates of individual clearance and volume of distribution versus covariates compared to those for the
structural model. For backward elimination, a P value cutoff of 0.001 (OFV increase, 10.8) was used.
Finally, we evaluated whether the model was physiologically plausible and contained clinically relevant
covariates.
The performance of the ﬁnal model was assessed by internal validation with a pcVPC based on 1,000
Monte Carlo simulations. Parameter precision was evaluated by nonparametric bootstrap analysis, using
1,000 data set replicates.
Monte Carlo simulation. Changes in exposure with increasing weight were visualized by performing
Monte Carlo simulations. The ﬁnal model was used to simulate different loading/maintenance anidula-
fungin regimens chosen at the discretion of the investigators, i.e., (i) the licensed 200-mg loading dose
and a 100-mg maintenance dose daily, (ii) a 25% increased dose consisting of a 250-mg loading dose and
TABLE 3 Anidulafungin studies and design included for analysis
Study Design and objective Phase
Anidulafungin
dose
No. of
subjects Population
No. of
samples PK sampling times (h)
ADOPT Single-dose, open-label study
evaluating PK
IV 100 mg i.v. over
90 min
8 Healthy Caucasian obese
males and females
88 0.5, 1, 1.5, 2, 4, 6, 8, 10,
12, 24, 48
VER002-1 Multiple-dose, open-label
study evaluating PK
I 100 mg i.v. over
90 min
5 Healthy Caucasian normal-wt
males and females
55 Predose,1.75, 2, 2.25, 2.5,
3.5, 5.5, 7.5, 9.5, 13.5,
23.75
XBAE Single-dose, open-label study
evaluating PK
I 100 mg i.v. over
90 min
7 Healthy Caucasian normal-wt
males
140 Predose, 0.17, 0.33, 0.5,
0.75, 1, 1.5, 2, 4, 6, 8,
12, 16, 24, 48, 72, 96,
120, 144, 168
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a 125-mg maintenance dose daily, and (iii) a 50% increased dose consisting of a 300-loading dose and
a 150-mg maintenance dose daily. A data set with a weight range from 60 to 170 kg was built with 5,000
subjects per 10-kg weight band, making a total of 55,000 virtual subjects. The AUC0–24 at steady state on
day 14 was calculated for each virtual subject.
No human pharmacodynamic target has been reported for anidulafungin. Therefore, we used the
pragmatic but arbitrary bioequivalence approach to determine the dose that obese patients should
receive to attain a median exposure within the criterion of a level of exposure of 80 to 125% of that for
normal-weight subjects (weight, between 60 and 80 kg) (23, 24).
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